Page 5 - Gianfranco Nazzi News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Gianfranco nazzi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Gianfranco Nazzi Today - Breaking & Trending Today

Almirall S A : solid core business Q1 performance boosted by growth drivers momentum


Almirall s solid core business Q1 performance boosted by growth drivers momentum
10 May 2021
Good business performance with significant growth in Core EBITDA: Core Net Sales €215.4 MM (+5% year-on-year) and Core EBITDA €68.0MM (+46% year-on-year).
Growth drivers momentum continues. Ilumetri® sales growing c.+90% year-on-year, Klisyri® launched successfully in the US in February 2021 and Seysara® modest rebound in line with the overall OAB market.
Gianfranco Nazzi joined as Almirall s new CEO on May 1st, 2021. His international experience and expertise in executing product launches will enable the company to deliver its global strategy and carry on the strategic roadmap.
Innovative pipeline with significant value still to be unlocked: expected upcoming approvals of Klisyri® and Wynzora® in Europe in Q2 2021, and lebrikizumab phase 3 ongoing with headline readout expected in H2 2021. ....

Comunidad Autonoma De Cataluna , Gianfranco Nazzi , Eli Lilly , University Of South Australia , Spanish Stock Exchange , University Of Dundee , Growth Drivers , Net Sales , Operating Cash Flow , Deferred Income , Medical Dermatology , Noble Purpose , காமுனிடட தன்னாட்சி டி கடலுள் , எலி லில்லி , பல்கலைக்கழகம் ஆஃப் தெற்கு ஆஸ்திரேலியா , ஸ்பானிஷ் ஸ்டாக் பரிமாற்றம் , பல்கலைக்கழகம் ஆஃப் டண்டீ , வளர்ச்சி இயக்கிகள் , நிகர விற்பனை , இயங்குகிறது பணம் ஓட்டம் , ஒத்திவைக்கப்பட்டது வருமானம் , மருத்துவ தோல் நோய் , உன்னத நோக்கம் ,

Almirall's solid core business Q1 performance boosted by Growth drivers momentum


Almirall s solid core business Q1 performance boosted by Growth drivers momentum
- Good business performance with significant growth in Core EBITDA: Core Net Sales €215.4 MM (+5% year-on-year) and Core EBITDA €68.0MM (+46% year-on-year)
- Growth drivers momentum continues. Ilumetri® sales growing c.+90% year-on-year, Klisyri® launched successfully in the US in February 2021 and Seysara® modest rebound in line with the overall OAB market
- Gianfranco Nazzi joined as Almirall s new CEO on May 1st, 2021. His international experience and expertise in executing product launches will enable the company to deliver its global strategy and carry on the strategic roadmap
- Innovative pipeline with significant value still to be unlocked: expected upcoming approvals of Klisyri® and Wynzora® in Europe in Q2 2021, and lebrikizumab phase 3 ongoing with headline readout expected in H2 2021 ....

Comunidad Autonoma De Cataluna , Prnewswire Almirall , Gianfranco Nazzi , Eli Lilly , University Of South Australia , University Of Dundee , Growth Drivers , Net Sales , Operating Cash Flow , Deferred Income , Medical Dermatology , காமுனிடட தன்னாட்சி டி கடலுள் , எலி லில்லி , பல்கலைக்கழகம் ஆஃப் தெற்கு ஆஸ்திரேலியா , பல்கலைக்கழகம் ஆஃப் டண்டீ , வளர்ச்சி இயக்கிகள் , நிகர விற்பனை , இயங்குகிறது பணம் ஓட்டம் , ஒத்திவைக்கப்பட்டது வருமானம் , மருத்துவ தோல் நோய் ,

Almirall S A : net profit falls 39% in Q1 as it looks for M&A opportunities


Message :
Required fields
BARCELONA, May 10 (Reuters) - Spanish pharmaceuticals group
Almirall said on Monday its first-quarter net profit
fell 38.7% to 29.8 million euros ($36.2 million) and revenues
by 10%, as the company looks for merger and acquisition (M&A)
opportunities.
The Barcelona-based firm continued to be hurt by the
pandemic as mobility restrictions led to fewer patients going to
the doctor, while sales suffered from generic competition in the
United States.
It said on Monday it predicts COVID-19 will continue to
affect its operations in the first half, before its impact
lessens in the second half of the year.
With Gianfranco Nazzi recently sworn as chief executive ....

United States , Comunidad Autonoma De Cataluna , Jorge Gallardo , Joan Faus , Jan Harvey , Gianfranco Nazzi , Israel Teva Pharmaceuticals Industries , Teva Pharmaceuticals Industries , Friday Almirall , Inti Landauro , ஒன்றுபட்டது மாநிலங்களில் , காமுனிடட தன்னாட்சி டி கடலுள் , ஜார்ஜ் கால்டொ , ஜோன் போச் , ஜான் ஹார்வி , தேவா மருந்துகள் தொழில்கள் ,